Fulgent Genetics Stock

Fulgent Genetics EBIT

The EBIT of Fulgent Genetics (FLGT) as of Aug 3, 2026 is -91.10 M USD. In the previous year, EBIT was -73.92 M USD — a change of 23.24% (lower).

EBIT

-91.10 MUSD

YoY

23.24%

Last updated:

In 2026, Fulgent Genetics's EBIT was -91.10 M USD, a 23.24% increase from the -73.92 M USD EBIT recorded in the previous year.

The Fulgent Genetics EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M USD)
Date
EBIT (M USD)
Jan 1, 2021
104.34 base
Jan 1, 2022
178.53 base
Jan 1, 2023
-195.53 base
Jan 1, 2024
-73.92 base
Jan 1, 2025
-91.10 base
Jan 1, 2026 (e)
-1.03 base
Jan 1, 2027 (e)
-1.18 base
Jan 1, 2028 (e)
-1.27 base
YEAREBIT (M USD)
2028 est -1.27
2027 est -1.18
2026 est -1.03
2025 -91.10
2024 -73.92
2023 -195.53
2022 178.53
2021 104.34
2020 290.16
2019 -0.43
2018 -5.06
2017 -3.40
2016 0.92
2015 -5.01
2014 -0.99
Access this data via the Eulerpool API

Fulgent Genetics Revenue

Fulgent Genetics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
992.58 M USD
104.34 M USD
104.34 M USD
Jan 1, 2022
618.97 M USD
178.53 M USD
143.40 M USD
Jan 1, 2023
289.21 M USD
-195.53 M USD
-167.83 M USD
Jan 1, 2024
283.47 M USD
-73.92 M USD
-42.71 M USD
Jan 1, 2025
322.67 M USD
-91.10 M USD
-60.51 M USD
Jan 1, 2026 (e)
352.20 M USD
-1.03 M USD
-47.91 M USD
Jan 1, 2027 (e)
401.70 M USD
-1.18 M USD
-35.55 M USD
Jan 1, 2028 (e)
434.90 M USD
-1.27 M USD
-30.60 M USD

Fulgent Genetics Margins

Fulgent Genetics stock margins

The Fulgent Genetics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Fulgent Genetics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Fulgent Genetics.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
78.29 %
10.51 %
10.51 %
Jan 1, 2022
59.28 %
28.84 %
23.17 %
Jan 1, 2023
36.12 %
-67.61 %
-58.03 %
Jan 1, 2024
37.82 %
-26.08 %
-15.07 %
Jan 1, 2025
40.56 %
-28.23 %
-18.75 %
Jan 1, 2026 (e)
40.56 %
-0.29 %
-13.60 %
Jan 1, 2027 (e)
40.56 %
-0.29 %
-8.85 %
Jan 1, 2028 (e)
40.56 %
-0.29 %
-7.04 %

Fulgent Genetics Stock analysis

What does Fulgent Genetics do? Fulgent Genetics Inc. is a US company founded in 2011 by Jianxing (Justin) Liu and Ming Hsieh. The company has undergone remarkable development and is now active in the field of genomics and genetics. Fulgent Genetics' business model is based on the development and distribution of solutions for the diagnosis of genetic diseases. The company offers a variety of products and services that enable doctors, clinics, and laboratories to make effective diagnoses based on genetics. One of Fulgent Genetics' main divisions is the Clinical Diagnostics department, which offers a wide range of diagnostic products that allow for both molecular diagnoses and the creation of clinical profiles for patients. This enables doctors and clinics to quickly and accurately detect and treat specific diseases. Another important division of Fulgent Genetics is the Research department, which focuses on the discovery and development of new technologies and testing procedures. These technologies and procedures are of great interest to the scientific community and are used in research or clinical studies. Fulgent Genetics also offers a Pharmacogenomics department, which is a growing segment in the personalized medicine market. The goal here is to tailor medications to the patient's genetic makeup. Fulgent Genetics' technology allows for the analysis of a patient's current genetic makeup and recommends medications based on that. Another important area of Fulgent Genetics is the direct-to-consumer sales of tests. This is particularly significant in the field of ancestry and genealogy research. Fulgent Genetics offers a variety of tests in this area and has already achieved great success. Overall, Fulgent Genetics offers a wide range of products and services mainly focused on the diagnosis of genetic diseases. However, the company also goes beyond that and provides solutions for a wide range of customers and applications. Fulgent Genetics is based in the US and has experienced rapid growth since its founding. The company's success is also reflected in the many awards it has received. It has been recognized multiple times and has established a reputation as one of the leading biotechnology companies in the world. Fulgent Genetics is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Fulgent Genetics's EBIT

Fulgent Genetics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Fulgent Genetics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Fulgent Genetics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Fulgent Genetics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Fulgent Genetics stock

EBIT of Fulgent Genetics is -91.10 M USD in 2026.

EBIT of Fulgent Genetics changed from -73.92 M USD to -91.10 M USD, representing a 23.24% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Fulgent Genetics since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Fulgent Genetics historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Fulgent Genetics

All Key Metrics — Fulgent Genetics